VEA
NGNE icon

Virtus ETF Advisers’s Neurogene NGNE Stock Holding History

Virtus ETF Advisers’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,183
Closed -$72.8K – 656
2024
Q4 		$72.8K Buy
3,183
+989
+45% +$36.8K 0.03% 354
2024
Q3 		$92.1K Buy
2,194
+38
+2% +$1.47K 0.04% 388
2024
Q2 		$78.5K Buy
+2,156
New +$76K 0.04% 411
2017
Q4 		– Sell
-1,193
Closed -$339K – 262
2017
Q3 		$339K Buy
1,193
+109
+10% +$31.3K 0.05% 126
2017
Q2 		$305K Buy
1,084
+180
+20% +$51.5K 0.05% 118
2017
Q1 		$302K Buy
904
+87
+11% +$30.6K 0.05% 134
2016
Q4 		$270K Buy
+817
New +$220K 0.08% 121

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Virtus ETF Advisers's NGNE Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Neurogene (NGNE) in Q1 2025, closing a stake of 3,183 shares — an estimated $72.8K sold.

Virtus ETF Advisers first reported a position in NGNE in Q4 2016 and held it in 7 quarters. The position peaked at $339K in Q3 2017. 85 funds tracked by Wall St. Rank hold NGNE as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Neurogene position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 3,183 Neurogene shares in Q1 2025, an estimated $72.8K.
  • Virtus ETF Advisers first reported a position in Neurogene in Q4 2016 and held it in 7 quarters.
  • Virtus ETF Advisers's Neurogene position peaked at $339K in Q3 2017.
  • 85 funds tracked by Wall St. Rank held Neurogene as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.